Crossmark

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis

Crossref DOI link: https://doi.org/10.1136/lupus-2017-000226

Published Online: 2017-09-14

Published Print: 2017-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Boedigheimer, Michael J

Martin, David A

Amoura, Zahir

Sánchez-Guerrero, Jorge

Romero-Diaz, Juanita

Kivitz, Alan

Aranow, Cynthia

Chan, Tak Mao

Chong, Yip Boon

Chiu, Kit

Wang, Christine

Sohn, Winnie

Arnold, Gregory E

Damore, Michael A

Welcher, Andrew A

Sullivan, Barbara A

Kotzin, Brian L

Chung, James B
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct00818948 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
https://doi.org/10.1136/lupus-2017-000226

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
https://doi.org/10.1016/s0140-6736(13)60889-2

nct00818948 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
https://doi.org/10.1136/lupus-2017-000226

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
https://doi.org/10.1016/s0140-6736(13)60889-2
Funding

Funding for this research was provided by:

Amgen Inc.